Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sino Biopharmaceutical Limited

http://www.sinobiopharm.com/index.html#/

Latest From Sino Biopharmaceutical Limited

October Outlook For US FDA Approvals: Goal Dates Are Sparse, But Backlog Looms

Upcoming user fee goal dates include AstraZeneca’s tremelimumab, Amicus’ AT-GAA, and drug delivery technology-driven NDAs from Supernus/US Worldmeds and scPharmaceuticals

US FDA Performance Tracker Drug Review

Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic

GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.

Deal Watch Business Strategies

Great Leap: Major Chinese Pharmas See Innovative Drug Sales Breakthrough in H1

A number of major Chinese pharma firms, including Simcere and Hansoh, brought in more revenues from innovative drugs than generics in the first half, a major stand-out from their domestic peers.

China Sales & Earnings

Dealmaking Quarterly Statistics, Q2 2022

During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.

Commercial Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Nutraceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Beijing Tide Pharmaceutical Co Ltd, invoX Pharma
    • Jiangsu Chia Tai Tianqing Pharmaceutical Co Ltd, Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd, Qingdao Chia Tai Haier Pharmaceutical Co Ltd, Jiangsu Chia Tai Qing Jiang Pharmaceutical Co Ltd, etc. Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
UsernamePublicRestriction

Register